Pro-Inflammatory cytokines & neurobehavioral symptoms in breast cancer patients

描述(申请人提供)：乳腺癌女性患者的促炎细胞因子和神经行为症状。摘要乳腺癌幸存者报告了令人衰弱的行为症状，如疲劳和神经认知功能障碍，这些症状在一些人身上甚至在治疗前基线就很明显。来自不同研究领域的充分证据表明，癌症相关的神经行为症状可能至少部分是由促炎细胞因子网络的激活驱动的。乳腺癌患者治疗前血清中特异性促炎细胞因子(IL-6、肿瘤坏死因子)和可溶性受体的浓度显著高于健康人水平，并具有预后价值；然而，这些治疗前升高与急性或慢性行为症状的相关性尚未得到评估。在乳腺癌幸存者中，在对化疗后几年的妇女的横断面研究中，循环sIL-6R和IL-1ra水平升高已成为持续性疲劳的显著生物标志物。目前还没有类似的工作在这类患者中发现神经认知功能障碍的生物标志物，也不知道这种细胞因子与疲劳或其他行为症状的联系是存在于更接近诊断期的地方，还是随着时间的推移而演变为“迟发效应”。在这项研究中，我们将解决这种知识差距，因为我们将在癌症治疗之前评估这种联系，并在治疗完成后再次评估这种联系。我们将在治疗前将至少137名乳腺癌患者与两个对照组进行比较，并在治疗后只对乳腺癌组进行纵向评估。这些发现有望增加我们对与乳腺癌患者神经行为症状相关的可能生物标记物的了解，以便更好地识别和治疗那些有这种影响的风险人群。公共卫生相关性：这些发现有望增加对与乳腺癌患者神经行为症状相关的可能生物标记物的了解，目的是更好地识别和治疗那些有这种影响的风险人群。

DESCRIPTION (provided by applicant): Pro-inflammatory cytokines and neurobehavioral symptoms in women with breast cancer. Abstract Survivors of breast cancer report debilitating behavioral symptoms, such as fatigue and neurocognitive dysfunction, which are evident in some individuals even at pre-treatment baseline. There is sufficient evidence from varied lines of research to propose that cancer-related neurobehavioral symptoms may be driven, at least in part, by activation of the pro-inflammatory cytokine network. Concentrations of specific pro-inflammatory cytokines (IL-6, TNF) and soluble receptors in serum obtained prior to treatment in breast cancer patients are significantly higher than levels found in healthy individuals and have prognostic value; however, these pre- treatment elevations have not yet been evaluated with respect to their association with either acute or chronic behavioral symptoms. Among survivors of breast cancer, elevated levels of circulating sIL-6R and IL-1ra have emerged as prominent biomarkers of persistent fatigue in cross-sectional studies of women several years post chemotherapy. No similar work has identified biomarkers of neurocognitive dysfunction in this patient population, and it is not known if the cytokine links with fatigue, or other behavioral symptoms, exist closer to the diagnosis period or evolve over time as "late effects". In this study, we will address this knowledge gap as we will evaluate this association prior to cancer treatment, and again following treatment completion. We will compare these associations in a minimum of 137 breast cancer patients relative to two comparison groups at pre-treatment, and longitudinally evaluate only the breast cancer group after treatment. Findings are expected to increase our knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects. PUBLIC HEALTH RELEVANCE: Findings are expected to increase knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects.